Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Slow Capital Inc.

Slow Capital Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 52.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 19,480 shares of the biopharmaceutical company's stock after acquiring an additional 6,715 shares during the period. Regeneron Pharmaceuticals accounts for about 1.7% of Slow Capital Inc.'s holdings, making the stock its 17th biggest position. Slow Capital Inc.'s holdings in Regeneron Pharmaceuticals were worth $12,355,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of REGN. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the last quarter. Proficio Capital Partners LLC increased its position in Regeneron Pharmaceuticals by 30.5% during the 4th quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 72 shares in the last quarter. American Assets Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $427,000. Independent Advisor Alliance lifted its position in Regeneron Pharmaceuticals by 117.3% during the fourth quarter. Independent Advisor Alliance now owns 478 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 258 shares in the last quarter. Finally, Avantax Advisory Services Inc. grew its stake in Regeneron Pharmaceuticals by 33.1% during the fourth quarter. Avantax Advisory Services Inc. now owns 1,624 shares of the biopharmaceutical company's stock worth $1,157,000 after buying an additional 404 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target for the company. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $823.54.

Regeneron Pharmaceuticals Stock Up 0.4%

NASDAQ:REGN traded up $2.07 on Thursday, reaching $550.00. The stock had a trading volume of 989,175 shares, compared to its average volume of 924,248. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $544.14 and a 200 day moving average of $616.16. The stock has a market cap of $59.38 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 2.03 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the company posted $9.55 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.